Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, reported its third quarter 2025 financial results and provided updates on key clinical programs. The company highlighted upcoming milestones, including top-line Phase 2a results for SGX302 in psoriasis and an enrollment update for its confirmatory Phase 3 HyBryte study in cutaneous T-cell lymphoma (CTCL).
CEO Christopher J. Schaber, PhD, confirmed that the first Data Monitoring Committee review found no safety concerns for HyBryte, maintaining a consistent safety profile across trials. This is a positive sign for the ongoing Phase 3 study, which is designed to support regulatory approvals worldwide. HyBryte (SGX301, synthetic hypericin sodium) is a novel photodynamic therapy using visible light for CTCL treatment.
Soligenix also reported $10.5 million in cash as of September 30, 2025, with an operating runway expected to extend through 2026. The company is evaluating strategic options to advance its late-stage pipeline, which includes SGX302 for psoriasis, dusquetide (SGX942) for oral mucositis, and SGX945 for Behcet's Disease. In addition, its Public Health Solutions segment is developing vaccines for ricin (RiVax), filoviruses, and COVID-19 (CiVax), supported by government funding from NIAID, DTRA, and BARDA.
For more details, view the full press release at https://ibn.fm/BA8C2. The latest news on SNGX is available at https://ibn.fm/SNGX.
